Találati lista | Tudóstér

001-es BibID:	BIBFORM118409
035-os BibID:	(cikkazonosító)e003777 (WoS)001153876600003 (Scopus)85183336004
Első szerző:	Molnár Gergő Attila
Cím:	Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study) / Gergő A Molnár, Zoltán Vokó, Gábor Sütő, György Rokszin, Dávid Nagy, György Surján, Orsolya Surján, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, Cecília Müller, Miklós Kásler, István Wittmann, Zoltan Kiss
Dátum:	2024
ISSN:	2052-4897
Megjegyzések:	INTRODUCTION: Type 2 diabetes mellitus is a risk factor for severe COVID-19 infection and is associated with increased risk of complications. The present study aimed to investigate effectiveness and persistence of different COVID vaccines in persons with or without diabetes during the Delta wave in Hungary. RESEARCH DESIGN AND METHODS: Data sources were the national COVID-19 registry data from the National Public Health Center and the National Health Insurance Fund on the total Hungarian population. The adjusted incidence rate ratios and corresponding 95% CIs were derived from a mixed-effect negative binomial regression model. RESULTS: A population of 672 240 cases with type 2 diabetes and a control group of 2?974?102 non-diabetic persons free from chronic diseases participated. Unvaccinated elderly persons with diabetes had 2.68 (95% CI 2.47 to 2.91) times higher COVID-19-related mortality rate as the 'healthy' controls. Primary immunization effectively equalized the risk of COVID-19 mortality between the two groups. Vaccine effectiveness declined over time, but the booster restored the effectiveness against mortality to over 90%. The adjusted vaccine effectiveness of the primary Pfizer-BioNTech against infection in the 14-120?days of postvaccination period was 71.6 (95% CI 66.3 to 76.1)% in patients aged 65-100?years with type 2 diabetes and 64.52 (95% CI 59.2 to 69.2)% in the controls. Overall, the effectiveness tended to be higher in individuals with diabetes than in controls. The booster vaccines could restore vaccine effectiveness to over 80% concerning risk of infection (eg, patients with diabetes aged 65-100?years: 89.1 (88.1-89.9)% with Pfizer-on-Pfizer, controls 65-100 years old: 86.9 (85.8-88.0)% with Pfizer-on-Pfizer, or patients with diabetes aged 65-100?years: 88.3 (87.2-89.2)% with Pfizer-on-Sinopharm, controls 65-100 years old: 87.8 (86.8-88.7)% with Pfizer-on-Sinopharm). CONCLUSIONS: Our data suggest that people with type 2 diabetes may have even higher health gain when getting vaccinated as compared with non-diabetic persons, eliminating the marked, COVID-19-related excess risk of this population. Boosters could restore protection.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk COVID-19 Diabetes Mellitus, Type 2 Mortality Vaccination
Megjelenés:	BMJ Open Diabetes Research & Care. - 12 : 1 (2024), p. 1-8. -
További szerzők:	Vokó Zoltán (1968-) (epidemiológus) Sütő Gábor Rokszin György Nagy Dávid Surján György Surján Orsolya Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Pálosi Mihály Müller Cecília Kásler Miklós Wittmann István Kiss Zoltán (Budapest)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM113488
035-os BibID:	(cikkazonosító)e065303 (Scopus)85158910226 (WoS)001001381400001
Első szerző:	Wéber András
Cím:	Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040 / András Wéber, Eileen Morgan, Jerome Vignat, Mathieu Laversanne, Margherita Pizzato, Harriet Rumgay, Deependra Singh, Péter Nagy, István Kenessey, Isabelle Soerjomataram, Freddie Bray
Dátum:	2023
ISSN:	2044-6055
Megjegyzések:	Objectives - Lung cancer (LC) is the leading cause of cancer death in 2020, responsible for almost one in five (18.0%) deaths. This paper provides an overview of the descriptive epidemiology of LC based on national mortality estimates for 2020 from the International Agency for Research on Cancer (IARC), and in the context of recent tobacco control policies. Design and setting - For this descriptive study, age-standardised mortality rates per 100?000 person-years of LC for 185 countries by sex were obtained from the GLOBOCAN 2020 database and stratified by Human Development Index (HDI). LC deaths were projected to 2040 based on demographic changes alongside scenarios of annually increasing, stable or decreasing rates from the baseline year of 2020. Results - LC mortality rates exhibited marked variations by geography and sex. Low HDI countries, many of them within sub-Saharan Africa, tend to have low levels of mortality and an upward trend in LC deaths is predicted for both sexes until 2040 according to demographic projections, irrespective of trends in rates. In very high HDI countries, including Europe, Northern America and Australia/New Zealand, there are broadly decreasing trends in men whereas in women, rates are still increasing or reaching a plateau. Conclusion - The current and future burden of LC in a country or region largely depends on the present trajectory of the smoking epidemic in its constituent populations, with distinct gender differences in smoking patterns, both in transitioning and transitioned countries. Further elevations in LC mortality are expected worldwide, raising important social and political questions, especially in low-income and middle-income countries.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	BMJ Open. - 13 : 5 (2023), p. 1-8. -
További szerzők:	Morgan, Eileen Vignat, Jerome Laversanne, Mathieu Pizzato, Margherita Rumgay, Harriet Singh, Deependra Nagy Péter (1976-) (vegyész) Kenessey István Soerjomataram, Isabelle Bray, Freddie
Pályázati támogatás:	TKP2021-EGA-44 Egyéb 2022-2.1.1-NL-2022-00010 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: